Ayuda-Durán P, Hanes R, Rønneberg L, Alver TN, Øy GF, Hauge S, Andersen AN, Egeland EV, Juell S, Nakken S, Asenso TQ, Zucknick M, Syljuåsen RG, Mælandsmo GM, Hovig E, Enserink JM (2026)
Systematic interrogation of drug sensitivities in melanoma reveals potent synergistic and antagonistic drug combinations with translational potential
Commun Med (Lond) (in press)
DOI 10.1038/s43856-026-01583-w, PubMed 42062484

Poissonnier A, Rugo HS, Horton W, Kim T, DeLuca A, Egeland EV, Cotechini T, Sivagnanam S, Mori M, Yu Y, Park B, Beelen N, Murugan D, Kirchberger N, Kummar S, Mayer IA, Blackwell K, Hwang ES, Coussens LM (2026)
CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors
Clin Cancer Res (in press)
DOI 10.1158/1078-0432.CCR-25-4236, PubMed 41894563

Brandal SHB, Mo T, Fangberget A, Nilsen LB, Geier OM, Bjørndal H, Holmen MM, Engebråten O, Garred Ø, Hole KH, Seierstad T (2026)
MRI for Predicting Response and 10-Year Outcome of Neoadjuvant Chemotherapy with or Without Additional Bevacizumab Treatment in HER2-Negative Breast Cancer
Cancers (Basel), 18 (3)
DOI 10.3390/cancers18030393, PubMed 41681863